Drugs / CAR70C1-ITNK
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT07336875 | Feb 2026 → Feb 2028 expected | acute myeloid leukemia | Tongji Hospital | Not yet recruiting | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CAR70C1-ITNK | “In vitro cytotoxicity assay data show that the activity of the tandem CAR-ITNK cells targeting both CD70 and CLL1 (CAR70C1-ITNK) in killing CD70- and CLL1-overexpressing cells...” NCT07336875 ↗ |
| Known as | CAR-ITNK | “In vitro cytotoxicity assay data show that the activity of the tandem CAR-ITNK cells targeting both CD70 and CLL1 (CAR70C1-ITNK) in killing CD70- and CLL1-overexpressing cells...” NCT07336875 ↗ |
| Action | Deplete | “in killing CD70- and CLL1-overexpressing cells” NCT07336875 ↗ |
| Modality | Cell therapy | “Participants will receive a single infusion of CAR-ITNK cell therapy targeting CD70 and CLL1” NCT07336875 ↗ |
| Target | CD70 | “the activity of the tandem CAR-ITNK cells targeting both CD70 and CLL1 (CAR70C1-ITNK)” NCT07336875 ↗ |